StandardX, a UK deep tech startup emerging from stealth on September 23, 2026, announced it has secured £10 million in seed funding to build what it describes as the world's first isotope refinery. The round was co-led by Vsquared Ventures and East X Ventures, with participation from firstminute capital, the UK Innovation & Science Seed Fund, Brevan Howard Macro Venture, and Geometry.
The London-based company plans to consolidate a sprawling, fragmented global supply chain for medical and fusion-grade isotopes into a single compact accelerator platform. If successful, the technology could address mounting shortages in radioactive materials used for targeted cancer therapies and fusion reactor fuel.
Demand for radiopharmaceuticals has accelerated sharply in recent years, propelled by new treatments that rely on hard-to-source isotopes such as lutetium-177 and actinium-225. Yet production remains scattered across aging nuclear reactors and single-purpose cyclotrons, many built decades ago. "Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn't kept pace," Lise Rechsteiner, general partner at Vsquared Ventures, said in a statement.
StandardX's pitch centers on deployability: one machine, multiple isotopes, positioned near hospitals and fusion facilities rather than thousands of miles away at centralized production sites.
A Notable Round in a Quieter Market
Curran Kalha, an investor at East X Ventures, called the deal "one of the largest UK deep tech rounds I've seen in a while" in a LinkedIn post on September 23, 2026. East X Ventures, the venture arm of London quantitative commodities firm East X, has been investing more aggressively in hard science startups. Vsquared Ventures, a European fund that previously backed rocket manufacturer Isar Aerospace and quantum computing firm IQM, has made isotope supply a strategic focus area.
The round signals continued investor appetite for capital-intensive infrastructure plays, even as venture funding for less tangible software startups has contracted. Deep tech companies with clear paths to addressing industrial bottlenecks appear to be weathering the downturn better than consumer-facing startups.
The Team Behind the Technology
StandardX now employs 15 people, according to the company, drawn from organizations including SpaceX, The London Clinic, Oxford, Cambridge, Fermilab, and the UK Atomic Energy Authority. Co-founder and CEO Richard Pearson earned a PhD in fusion engineering and previously worked at Kyoto Fusioneering, where he specialized in tritium supply chains. Co-founder and CTO Ross Allen, who holds a PhD in nuclear physics, has founded two prior startups.
Recent additions include Jeff Peachman, who spent over a decade at SpaceX working on Falcon 9 and Starlink systems, and Dr. Carol Johnston from Fermilab, per the company's website. UK Companies House records indicate the company formally incorporated on August 22, 2025.
A Compact Accelerator for Multiple Isotopes
At the core of StandardX's technology is a compact, high-power fixed-field alternating gradient particle accelerator. The platform is designed to produce a portfolio of medical, industrial, and energy isotopes from a single machine, rather than requiring separate facilities for each isotope type.
The company says it has engineered the system for high uptime using advanced materials and real-time optimization through what it calls a "physics-informed digital twin" powered by AI. The refinery fits within a standard industrial footprint, which the company argues allows deployment closer to end users and avoids the logistical headaches of shipping short-lived radioactive materials across continents.
StandardX's 2027 roadmap targets isotopes including astatine-211, copper-64, and zirconium-89 for cancer diagnostics and therapy. The company plans to expand into actinium-225, lutetium-177, and technetium-99m in subsequent phases. Perhaps more ambitiously, StandardX intends to produce tritium, the scarce radioactive hydrogen isotope required for fusion fuel. Only about 25 kilograms of tritium exist globally today, according to the company, and virtually all of it is allocated to existing defense applications or research reactors.
A Crowded but Growing Field
StandardX enters a landscape already populated by established producers and new entrants racing to expand capacity. NorthStar Medical Radioisotopes confirmed routine commercial-scale actinium-225 production using electron accelerators in January, while Missouri University Research Reactor announced broader availability of GMP-grade lutetium-177 in March, according to company statements. Established players such as ITM Radiopharma, BWXT Medical, and Curium have been scaling up operations to meet demand from pharmaceutical developers.
Current isotope production splits across reactors for lutetium-177 and molybdenum-99, cyclotrons for fluorine-18 and copper-64, and a handful of electron-beam facilities. A September industry report from Sleuth Insights estimated the radioligand therapy market at roughly $13.5 billion in 2026, with bottlenecks emerging not just in production but in delivery infrastructure.
"StandardX is tackling a supply problem that matters enormously today in medicine," Theodore Mollinger, general partner at East X Ventures, said in a statement. Tech.eu reported Tuesday that the company has signed agreements with fusion developers, though StandardX declined to name the counterparties.
Next Steps and Timeline
The seed capital will fund hiring, secure StandardX's first industrial site in London, and advance construction of the accelerator platform. The startup aims to deliver its first isotopes to a medical research partner in 2027 and reach industrial-scale production by 2029.
"Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply," CEO Pearson told Tech.eu on Tuesday. Whether StandardX can deliver on that promise at commercial scale remains to be seen, but the company has assembled a team and investor base that suggests the challenge is being taken seriously.
